Profile data is unavailable for this security.
About the company
MedMira Inc. is a Canada-based developer and manufacturer of Rapid Vertical Flow (RVF) diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. It provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.
- Revenue in CAD (TTM)383.32k
- Net income in CAD-3.11m
- Incorporated1999
- Employees65.00
- LocationMedMira Inc155 Chain Lake Dr.,, Suite 1HALIFAX B3S 1B3CanadaCAN
- Phone+1 (902) 450-1588
- Fax+1 (902) 450-1580
- Websitehttps://medmira.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enablence Technologies Inc | 2.01m | -15.31m | 33.47m | 202.00 | -- | -- | -- | 16.61 | -0.8237 | -0.8237 | 0.1084 | -1.48 | 0.7554 | 8.16 | 6.81 | -- | -574.25 | -191.45 | -- | -- | -146.33 | -61.64 | -760.20 | -250.29 | 0.1519 | -2.88 | -- | -- | -0.8595 | -10.36 | -173.59 | -- | 5.99 | -- |
| Theralase Technologies Inc | 1.04m | -4.43m | 40.17m | 0.00 | -- | 20.87 | -- | 38.67 | -0.0199 | -0.0199 | 0.0047 | 0.0086 | 0.3222 | 0.8483 | 3.66 | -- | -137.39 | -69.79 | -198.84 | -81.78 | 51.19 | 37.49 | -426.36 | -557.68 | 0.9119 | -- | 0.156 | -- | -6.00 | -9.20 | 12.69 | -- | -22.53 | -- |
| Nanalysis Scientific Corp | 34.95m | -14.76m | 44.11m | 130.00 | -- | 1.71 | -- | 1.26 | -0.1457 | -0.1457 | 0.3519 | 0.228 | 0.5745 | 4.25 | 5.14 | 268,876.90 | -24.63 | -18.30 | -36.68 | -25.35 | 18.23 | 42.75 | -42.87 | -39.01 | 1.11 | -2.27 | 0.4119 | -- | 14.69 | 27.71 | -63.35 | -- | 15.35 | -- |
| Medmira Inc | 383.32k | -3.11m | 64.65m | 65.00 | -- | -- | -- | 168.65 | -0.0045 | -0.0045 | 0.0006 | -0.024 | 0.0752 | 0.7431 | 0.2848 | -- | -61.10 | -69.95 | -- | -- | 62.61 | 66.76 | -812.38 | -187.61 | 0.2112 | -1.96 | -- | -- | -54.57 | -5.98 | -46.08 | -- | -- | -- |
| Sernova Corp | 0.00 | -41.32m | 71.35m | -- | -- | -- | -- | -- | -0.1362 | -0.1362 | 0.00 | -0.0181 | 0.00 | -- | -- | -- | -165.95 | -74.84 | -303.82 | -85.03 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -59.69 | -- | -2.91 | -- |
